Tuesday, October 17, 2017 9:38:01 AM
[ACCESSWIRE]
ACCESSWIREOctober 17, 2017
Research Study to Focus on Actionable Mutations in Non-Small Cell Lung Cancer (NSCLC)
NEW HAVEN, CT / ACCESSWIRE / October 17, 2017 / Precipio, Inc. (PRPO), announced today that its ICE COLD-PCR™ technology has been selected for a study to identify clinically actionable mutations in Non-Small Cell Lung Cancer at the University of Kentucky's Markey Cancer Center, a National Cancer Institute (NCI)-designated center.
"The study will focus on actionable mutations for non-small lung cancer in EGFR, KRAS and BRAF," said Dr. Kurt B. Hodges, Director, Molecular Oncology Services, who will lead the study. "Our goal is to use this technology to identify patients with clinically actionable mutations in NSCLC and then monitor these patients for treatment response via resistance mutations to commonly prescribed NSCLC drugs. Our department has considered numerous technologies for this study, and concluded that Precipio's ICE COLD-PCR™ (ICP) was the most suitable because ICP is a non-allele specific technology with a sensitivity that will allow our laboratory to cost-effectively pick up critical clinically actionable mutations at very low levels in plasma and test for these mutations at several time points over the course of therapy."
The study is scheduled to commence during the fourth quarter of 2017 and is expected to enroll 100 patients. This research study investigates the potential for the technology as a cutting-edge, cost-effective solution that enriches mutations to achieve a high level of sensitivity. Given the design of research studies such as this to conduct repeat testing over time to monitor disease progression, there is a substantive need for an inexpensive, cost-effective solution that creates a feasible, economically viable application of the promise of liquid biopsies.
"We are delighted to partner with the University of Kentucky to support this important research study, especially in light of the recent launch of our first re-designed ICE-COLD PCR™ targeted enrichment kit," said Ilan Danieli, President and Chief Executive Officer of Precipio. "While the field of liquid biopsies is undoubtedly going to change the way cancer is treated over the next few years, valuable research like this is still needed to establish clinical validity and applicability of blood-based samples and corresponding technologies. Academic centers play a key role in the forefront of research to establish these standards, and we are honored to be a part of that process. Precipio is committed to playing a key role in working with researchers and academic institutions to help demonstrate the value of ICE COLD-PCR™ as a leading technology within the liquid biopsy field," Mr. Danieli concluded.
ICE COLD-PCR™ delivers up to a 500-fold increase in mutation detection compared to most current methods, with levels of detection down to 0.1%, making it an ideal method for liquid biopsy analyses. As a low-cost product, it provides a game-changing alternative to competing high-priced liquid biopsy platforms as an economically viable technology that enables low-cost repeat testing.
About University of Kentucky's Markey Cancer Center
The UK Markey Cancer Center was founded in 1983 and is a dedicated matrix cancer center established as an integral part of the University of Kentucky and the UK HealthCare enterprise. It has provided state-of-the-art cancer care for more than 20 years. Markey is the only cancer center in Kentucky designated by the National Cancer Institute. In August 2017, Markey was designated as one of the Top 50 Cancer Centers in the nation by U.S. News & World Report. Markey Cancer Center provides access to more than 100 nationally sponsored clinical studies for different types of cancer. It is among the few institutions nationwide providing multidisciplinary care through Clinical Care and Research Teams (CCARTs). Major CCARTs include breast, gynecologic, gastrointestinal, head and neck, lung, brain, hematologic and genitourinary cancers.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise, and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
https://finance.yahoo.com/news/precipios-ice-cold-pcr-tm-120000416.html
Recent PRPO News
- Precipio Announces Year end 2023 Shareholder Update Call • GlobeNewswire Inc. • 03/25/2024 09:00:00 PM
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY • GlobeNewswire Inc. • 02/13/2024 03:00:00 PM
- Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer • GlobeNewswire Inc. • 02/06/2024 03:00:00 PM
- Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter • GlobeNewswire Inc. • 01/23/2024 03:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 09:05:44 PM
- Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan • GlobeNewswire Inc. • 01/17/2024 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:33:26 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 10:01:11 PM
- Precipio Announces Christina Valauri joins the Board of Directors • GlobeNewswire Inc. • 01/02/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 10:00:22 PM
- Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024 • GlobeNewswire Inc. • 12/14/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:15:16 PM
- Precipio Announces Q3-2023 Shareholder Update Call • GlobeNewswire Inc. • 11/16/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 08:30:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:30:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:30:25 PM
- Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022 • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 08:34:18 PM
- Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023 • GlobeNewswire Inc. • 10/03/2023 02:00:00 PM
- Precipio Continues to Sign New HemeScreen™ Customers • GlobeNewswire Inc. • 09/28/2023 01:00:00 PM
- Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven • GlobeNewswire Inc. • 09/25/2023 03:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/21/2023 09:10:33 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM